WELCOME TO ADELICE 
Adelice Orphan Diseases Advancement™
Our core focus is developing novel treatments for cystic fibrosis - rare pulmonary disease - and other rare diseases. In addition to R&D, we also act as a specialized distributor, ensuring that our breakthrough therapies and other essential medical products reach healthcare providers efficiently.
About Us
Adelice™ S.A. is a pharmaceutical research and development (R&D) company focused on innovative drug development and pharmaceutical advancements. Our primary objective is to develop and provide high-quality, life-saving medications and healthcare products that address critical medical needs.
In addition to R&D, we also act as a specialized distributor, ensuring that our breakthrough therapies and other essential medical products reach healthcare providers efficiently. Our core focus is developing novel treatments for cystic fibrosis - rare pulmonary disease - and other rare diseases, adhering to the highest industry standards and regulatory frameworks.
Mission Statement
To be a leading research and development company, dedicated to discovering, developing, and distributing high-quality and affordable medicinal products for patients with rare and serious diseases.
Our Industry: Pharmaceutical Research & Development, Pharmaceutical Distribution
Our Key Services:
* Pharmaceutical research and drug development to address unmet medical needs,
* Procurement of high-quality pharmaceutical products,
* Regulatory and clinical research compliance to ensure efficacy and safety,
* Storage, inventory management, and distribution of innovative treatments to healthcare providers.
Our Products
Our flagship innovation is Trilexa®, a proprietary treatment for cystic fibrosis. Trilexa® combines three active components - elexacaftor, ivacaftor, and tezacaftor - to address the genetic mutations causing cystic fibrosis, effectively slowing disease progression and improving patient outcomes.
Research & Development Focus:
Development of novel formulations targeting rare and complex diseases
Preclinical and clinical research to enhance drug efficacy
Collaboration with biotech firms and academic institutions to drive innovation
About Cystic Fibrosis (CF):
Cystic fibrosis is a genetic disorder that severely impacts respiratory and digestive functions due to mutations in the CFTR gene. Patients experience: Chronic respiratory infections;
Nutritional deficiencies due to poor absorption;
Progressive lung damage and reduced life expectancy.
While there is no definitive cure, Trilexa® represents a scientific breakthrough in managing symptoms and enhancing quality of life for CF patients.
Trilexa® is classified as an orphan medicinal product, qualifying for government incentives and regulatory support to accelerate its availability.
Read more about the drug development for rare diseases affecting children here.
Contact Us
For inquiries or more information about our products and services,
feel free to reach out to us.
Adelice S.A.
Email: info@adelicepharma.com